全球创新药研发趋势与重点研发领域

采用文献研究、比较研究方法，介绍了全球创新药研发趋势与重点研发领域。医药市场欧美继续保持领导地位，同时新兴市场崛起；新药投入产出比降低，临床试验复杂性增加；传统活跃领域仍是研发的侧重点，但罕见药受到重视，个体化研发时代到来。制药企业应目标明确，关注热点领域，才能维持企业的不断创新。

Targeted inhibition of inflammation in cardiovascular disease

Inflammation plays a fundamental role in atherosclerosis.Yet,whether direct inhibition of inflammation will reduce the occurrence of adverse cardiovascular outcomes is unkown.Low-dose methotrexate（LDM）,or canakinumab（a monoclonal antihuman IL-1β antibody）could reduce several inflammatory biomarkers without substantive effects on lipid levels,hemostasis,and platelet function.CANTOS and CIRT trails will enroll more than 25,000 patients worldwide.Each trial uses an event-driven protocol to address whether IL-1inhibition with canakinumab（CANTOS）or LDM（CIRT）can reduce rates of recurrent myocardial infarction,stroke,and cardiovascular death as compared to placebo in stable coronary artery disease patients with a persistent pro-inflammatory response（in CIRT using the additional entry criteria of the presence of either diabetes or metabolic syndrome and in CANTOS using the additional entry criteria of hs-CRP 2mg/L）.Together,both trials would support the inflammatory hypothesis of atherosclerosis and serve as catalyst for the development of novel therapeutic agents focused specifically on vascular inflammation.